本回顾性研究调查了韩国癌症中心医院(首尔,韩国)。纳入2000年1月至2023年5月接受肉瘤治疗后被诊断患有SHM的患者。从患者病历中收集临床数据。分析临床特点,包括SHM发病率,类型和预后。在2,953例肉瘤患者中,18例(0.6%)被诊断为SHM。他们在肉瘤诊断时的中位年龄为39.5(范围,9-72)年,这些患者中74%(n=14)为男性。肉瘤的组织学特征各不相同,9例(50%)诊断为骨肉瘤。所有肉瘤患者均行手术治疗,16例(88.8%)接受化疗。最常见的SHM类型是急性髓系白血病(n=6;33.3%),其次是骨髓增生异常综合征(n=5;27.7%)。肉瘤诊断和SHM鉴定之间的中位潜伏期为30(范围,11-121)个月。共有13例(72.2%)患者接受了SHM治疗。SHM诊断后的中位总生存期为15.7(范围,0.4-154.9)个月。本研究中肉瘤中SHM的发生率与先前报道的一致。SHM的存在与患者预后不良相关,特别是如果没有给予SHM治疗。
The present retrospective study investigated the clinical features and prognosis of secondary hematological malignancies (SHMs) in patients with sarcoma at Korea Cancer Center Hospital (Seoul, South Korea). Patients who had been diagnosed with SHMs after having received treatment for sarcoma between January 2000 and May 2023 were enrolled. Clinical data were collected from the patients\' medical records. Clinical characteristics were analyzed, including
SHM incidence, type and prognosis. Of 2,953 patients with sarcoma, 18 (0.6%) were diagnosed with SHMs. Their median age at the time of sarcoma diagnosis was 39.5 (range, 9-72) years, and 74% (n=14) of these patients were male. The histological features of sarcoma varied, with osteosarcoma diagnosed in nine patients (50%). All patients with sarcoma underwent surgical treatment, and 16 (88.8%) received chemotherapy. The most common type of SHMs was acute myeloid leukemia (n=6; 33.3%), followed by myelodysplastic syndrome (n=5; 27.7%). The median latency period between the sarcoma diagnosis and
SHM identification was 30 (range, 11-121) months. A total of 13 (72.2%) patients received treatment for the
SHM. The median overall survival after
SHM diagnosis was 15.7 (range, 0.4-154.9) months. The incidence of SHMs in sarcoma in the present study was consistent with that reported previously. The presence of SHMs was associated with a poor patient prognosis, especially if treatment for SHMs was not administered.